• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[成人李斯特菌病。10例病例回顾]

[Listeriosis in the adult. Revision of 10 cases].

作者信息

Arias Miranda I M, Nuño Mateo F J, Noval Menéndez J, Fonseca Aizpuru E M, Menéndez Calderón M J

机构信息

Servicio de Medicina Interna, Hospital de Cabueñes, Gijón, Asturias.

出版信息

An Med Interna. 2004 Feb;21(2):75-8. doi: 10.4321/s0212-71992004000200006.

DOI:10.4321/s0212-71992004000200006
PMID:14974893
Abstract

Listeria monocytogenes is still a very rare opportunist infection in immunosuppressive patients. The clinical-epidemiological and therapeutic characteristics in 10 patients with infection produced by LM are reported--four of them had primary bacteriemia, three patients had a meningeal involvement, there were two patients with spontaneous bacterial peritonitis and one suffered from abdominal access. All of the patients had underlying disorders favouring the infection. Sepsis and meningeal syndrome were the most common presenting forms. Ampicillin was the most used antibiotic. The overall mortality was 40%.

摘要

单核细胞增生李斯特菌在免疫抑制患者中仍是一种非常罕见的机会性感染。本文报告了10例由单核细胞增生李斯特菌感染患者的临床流行病学和治疗特征——其中4例患有原发性菌血症,3例有脑膜受累,2例患有自发性细菌性腹膜炎,1例患有腹部感染。所有患者均有易引发感染的基础疾病。败血症和脑膜综合征是最常见的表现形式。氨苄青霉素是最常用的抗生素。总死亡率为40%。

相似文献

1
[Listeriosis in the adult. Revision of 10 cases].[成人李斯特菌病。10例病例回顾]
An Med Interna. 2004 Feb;21(2):75-8. doi: 10.4321/s0212-71992004000200006.
2
[A Touraine cluster of central nervous system listeriosis].图赖讷地区中枢神经系统李斯特菌病聚集性病例
Med Mal Infect. 2011 Nov;41(11):613-6. doi: 10.1016/j.medmal.2011.07.015. Epub 2011 Sep 9.
3
Listeriosis.李斯特菌病
Clin Infect Dis. 1997 Jan;24(1):1-9; quiz 10-1. doi: 10.1093/clinids/24.1.1.
4
Disease Burden of Invasive Listeriosis and Molecular Characterization of Clinical Isolates in Taiwan, 2000-2013.2000 - 2013年台湾侵袭性李斯特菌病的疾病负担及临床分离株的分子特征
PLoS One. 2015 Nov 10;10(11):e0141241. doi: 10.1371/journal.pone.0141241. eCollection 2015.
5
Listeria monocytogenes-associated spontaneous bacterial peritonitis in France: a nationwide observational study of 208 cases.法国李斯特菌相关性自发性细菌性腹膜炎:208 例全国性观察研究。
Lancet Infect Dis. 2024 Jul;24(7):783-792. doi: 10.1016/S1473-3099(24)00151-8. Epub 2024 Apr 9.
6
Listeriosis in adults: a changing pattern. Report of eight cases and review of the literature, 1968-1978.成人李斯特菌病:一种不断变化的模式。8例报告及1968 - 1978年文献综述
Rev Infect Dis. 1980 Mar-Apr;2(2):207-27. doi: 10.1093/clinids/2.2.207.
7
Peritonitis as the First Presentation of Disseminated Listeriosis in a Patient on Peritoneal Dialysis-a Case Report.腹膜炎作为腹膜透析患者播散性李斯特菌病的首发表现——病例报告
Perit Dial Int. 2017 Mar-Apr;37(2):239-240. doi: 10.3747/pdi.2016.00205.
8
Clinical and microbiological characteristics and follow-up of invasive Listeria monocytogenes infection among hospitalized patients: real-world experience of 16 years from Hungary.住院患者侵袭性李斯特菌感染的临床和微生物学特征及随访:来自匈牙利 16 年的真实世界经验。
BMC Microbiol. 2024 Sep 6;24(1):325. doi: 10.1186/s12866-024-03478-z.
9
[Listeriosis in the adult. Clinical, epidemiological, and therapeutic considerations based on a series of 26 cases].[成人李斯特菌病。基于26例病例的临床、流行病学及治疗考量]
Enferm Infecc Microbiol Clin. 1990 Aug-Sep;8(7):414-9.
10
Epidemiology and treatment of the commonest form of listeriosis: meningitis and bacteraemia.最常见的李斯特菌病形式:脑膜炎和菌血症的流行病学与治疗。
Infez Med. 2017 Sep 1;25(3):210-216.

引用本文的文献

1
[Spontaneous bacterial peritonitis caused by Listeria monocytogenes: eight case reports (1992-2017) and literature review].[由单核细胞增生李斯特菌引起的自发性细菌性腹膜炎:8例报告(1992 - 2017年)及文献综述]
Rev Esp Quimioter. 2018 Dec;31(6):532-536. Epub 2018 Oct 22.
2
Listeriosis in Portugal: an existing but under reported infection.葡萄牙的李斯特菌病:一种已存在但报告不足的感染病。
BMC Infect Dis. 2006 Oct 20;6:153. doi: 10.1186/1471-2334-6-153.